Your browser doesn't support javascript.
loading
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches.
Gao, Qiang; Mechin, Ingrid; Kothari, Nayantara; Guo, Zhuyan; Deng, Gejing; Haas, Kimberly; McManus, Jessica; Hoffmann, Dietmar; Wang, Anlai; Wiederschain, Dmitri; Rocnik, Jennifer; Czechtizky, Werngard; Chen, Xin; McLean, Larry; Arlt, Heike; Harper, David; Liu, Feng; Majid, Tahir; Patel, Vinod; Lengauer, Christoph; Garcia-Echeverria, Carlos; Zhang, Bailin; Cheng, Hong; Dorsch, Marion; Huang, Shih-Min A.
Afiliação
  • Gao Q; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Mechin I; Tucson Research Center, Sanofi, Tucson, Arizona 85755.
  • Kothari N; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Guo Z; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Deng G; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Haas K; Lead Generation and Candidate Realization, Sanofi, Bridgewater, New Jersey 08807, and.
  • McManus J; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Hoffmann D; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Wang A; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Wiederschain D; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Rocnik J; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Czechtizky W; Lead Generation and Candidate Realization, Sanofi, Industriepark Höchst, 65926 Frankfurt, Germany.
  • Chen X; Lead Generation and Candidate Realization, Sanofi, Bridgewater, New Jersey 08807, and.
  • McLean L; Lead Generation and Candidate Realization, Sanofi, Bridgewater, New Jersey 08807, and.
  • Arlt H; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Harper D; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Liu F; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Majid T; Lead Generation and Candidate Realization, Sanofi, Waltham, Massachusetts 02451.
  • Patel V; Lead Generation and Candidate Realization, Sanofi, Waltham, Massachusetts 02451.
  • Lengauer C; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Garcia-Echeverria C; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Zhang B; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Cheng H; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Dorsch M; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France.
  • Huang SA; From Discovery and Early Development, Sanofi Oncology, Cambridge, Massachusetts 02139 and 94400 Vitry-sur-Seine Cedex, France,. Electronic address: alex.huang@sanofi.com.
J Biol Chem ; 288(42): 30125-30138, 2013 Oct 18.
Article em En | MEDLINE | ID: mdl-24003220
ABSTRACT
PRP4 kinase is known for its roles in regulating pre-mRNA splicing and beyond. Therefore, a wider spectrum of PRP4 kinase substrates could be expected. The role of PRP4 kinase in cancer is also yet to be fully elucidated. Attaining specific and potent PRP4 inhibitors would greatly facilitate the study of PRP4 biological function and its validation as a credible cancer target. In this report, we verified the requirement of enzymatic activity of PRP4 in regulating cancer cell growth and identified an array of potential novel substrates through orthogonal proteomics approaches. The ensuing effort in structural biology unveiled for the first time unique features of PRP4 kinase domain and its potential mode of interaction with a low molecular weight inhibitor. These results provide new and important information for further exploration of PRP4 kinase function in cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ribonucleoproteína Nuclear Pequena U4-U6 / Inibidores de Proteínas Quinases / Proteínas de Neoplasias / Neoplasias Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2013 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ribonucleoproteína Nuclear Pequena U4-U6 / Inibidores de Proteínas Quinases / Proteínas de Neoplasias / Neoplasias Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2013 Tipo de documento: Article País de afiliação: França